bioMerieux clinches MicroStreak technology:
This article was originally published in Clinica
Executive Summary
French in vitro diagnostics company bioMerieux has clinched an exclusive worldwide licence for MicroStreak, a fully-automated pre-poured media (PPM) streaker used in microbiology labs. The robotic system, developed by Australia's LabTech Systems, is used to replace the manual and time-consuming task of streaking the agar plates before they are sent for analysis. The MicroStreaker, which is at an advanced stage of development, will be launched in 2008, with the US and Europe as bioMerieux's primary target markets, a company spokesperson told Clinica. She added that the addition of MicroStreak to bioMerieux's current PPM portfolio would be "positive and synergistic". Under the terms of the licensing agreement, the Marcy L'Etoile firm will pay LabTech an upfront fee of E2m ($2.7m) and a further E5m in milestone payments. The companies have also agreed on minimum royalties for certain regions.
You may also be interested in...
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.